Researchers have developed new liquid biopsy blood tests capable of detecting multiple cancers, liver diseases, and microscopic genetic warning signs years before traditional symptoms appear or routine diagnostics flag trouble, according to recent studies published across major scientific journals.
The landscape of early disease detection is shifting away from reactive diagnosis and toward proactive screening. Recent scientific findings from multiple research teams highlight how circulating DNA in the human bloodstream can expose hidden biological vulnerabilities, tumor mutations, and organ stress long before an individual ever feels sick.
MethylScan Blood Test Targets Multiple Cancers and Liver Conditions at Low Cost
A team of researchers at the University of California, Los Angeles (UCLA) has created a simple, relatively inexpensive blood test known as MethylScan to simultaneously identify multiple solid-tumor cancers and liver diseases from a single blood draw. Described in the Proceedings of the National Academy of Sciences, the technique analyzes cell-free DNA (cfDNA)—small, fragmented pieces of genetic material that enter the bloodstream when cells die naturally.
Because an average adult human loses roughly 50 to 70 billion cells daily, their corresponding DNA circulates widely, carrying molecular fingerprints from across the body. Rather than hunting exclusively for rare genetic mutations like traditional liquid biopsies, the UCLA method focuses on DNA methylation patterns, which are chemical modifications that govern gene activity across different tissue types.
Overcoming background noise has historically been the primary obstacle in cfDNA diagnostics. Roughly 80% to 90% of circulating genetic material originates from normal blood cells, which can easily obscure faint tumor signals. To bypass this, the UCLA team utilized specialized enzymes to selectively cut away unmethylated DNA fragments from blood cells before sequencing.
“The test focuses on methylation-informative genome regions and eliminates 80 to 90% cell-free DNA that originates from blood cells.”
Jasmine Zhou, PhD, senior author and professor of pathology and laboratory medicine at the UCLA Health Jonsson Comprehensive Cancer Center
This selective background reduction significantly reduces sequencing needs. The team estimates that running the test could cost less than $20 per sample, making it substantially more affordable than many existing multi-cancer screening tools.
Accuracy Rates Across 1,061 Patient Samples
Using machine learning algorithms to interpret complex methylation patterns, the method achieved notable performance benchmarks.
| Metric / Patient Group | Observed Performance |
|---|---|
| Overall Cancer Detection Rate (All Stages) | Approximately 63% at 98% specificity |
| Early-Stage Cancer Detection | Roughly 55% at 98% specificity |
| High-Risk Liver Cancer Surveillance | Nearly 80% of cases detected in patients with cirrhosis or HBV |
Beyond simply flagging disease, the methylation patterns also provided information regarding the tissue of origin. Dr. Wenyuan Li, a co-corresponding author of the study, noted that tracing signals back to their specific biological source is essential for directing patients toward appropriate follow-up imaging or diagnostic procedures.
Tracking Blood Cancer Years Early
In parallel research published in Cancer Discovery, scientists monitored 30 people with myeloproliferative neoplasms (MPNs)—a group of blood cancers in which the bone marrow produces too many blood cells—to see if DNA patterns could predict disease progression. The study revealed that patients whose disease eventually worsened often accumulated harmful mutations years before routine blood tests could detect changes.
Broader Biomarkers: Low Testosterone and Future Health Risks
Genetic alterations are not the only biological indicators showing up in blood tests years prior to diagnosis. A large international analysis published in Lancet Healthy Longevity—the Androgens In Men Study (AIMS)—analyzed data from more than 26,000 men across Australia, the United States, and Europe to examine the relationship between hormone levels and cancer outcomes.
Led by Professor Bu Yeap of The University of Western Australia, the meta-analysis found that men with testosterone levels in the lowest one-fifth of the study group faced an 18 percent higher risk of dying from cancer compared to those in the highest one-fifth. However, prostate cancer did not follow this pattern; prostate risks were instead linked to lower levels of sex hormone-binding globulin and luteinizing hormone.
Researchers caution that low testosterone does not directly cause cancer, nor would hormone supplements prevent it. Instead, investigators emphasize that declining endocrine markers serve as an important broader biomarker of reduced physical resilience and underlying health vulnerabilities, prompting recommendations for comprehensive medical checkups.
